Related Experiment Video
Updated: Jul 21, 2026
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified
M Cohen1, E M Antman, E P Gurfinkel
1Division of Cardiology, MCP-Hahnemann University School of Medicine, Philadelphia, Pennsylvania 19102-1192, USA. cohen@tenethealth.com
Insights
Enoxaparin, a low-molecular-weight heparin, is more effective than unfractionated heparin for patients with non-ST-segment elevation myocardial infarction. Specific patient subgroups, including those with ST-segment changes, showed greater benefit from enoxaparin treatment.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Two major trials (ESSENCE, TIMI 11B) compared enoxaparin to unfractionated heparin (UFH) in non-ST-segment elevation myocardial infarction (NSTEMI).
- Enoxaparin demonstrated superior efficacy over UFH in reducing adverse cardiac events in NSTEMI patients.
- NSTEMI patients represent a heterogeneous group, necessitating subgroup analysis for treatment optimization.
Purpose of the Study:
- To perform a meta-analysis of pooled data from ESSENCE and TIMI 11B.
- To investigate the efficacy of enoxaparin in various patient subgroups within NSTEMI.
- To identify factors predicting enhanced treatment response to enoxaparin.
Main Methods:
- Meta-analysis of pooled data from ESSENCE and TIMI 11B trials.
- Development of a statistical model to identify predictors of treatment effect.
- Analysis of patient subgroups based on clinical characteristics and biomarkers.
Main Results:
- Enoxaparin proved more effective than UFH in reducing the composite endpoint (death, MI, urgent revascularization) across most subgroups at 43 days.
- Patients with ST-segment deviation, elevated cardiac enzymes, women, nonsmokers, and those with higher cardiac risk factors (prior PCI, age ≥65, prior angina, prior aspirin) showed greater enoxaparin benefit.
- Multivariate analysis identified ST-segment depression and electrocardiographic changes as key predictors of enhanced enoxaparin efficacy.
Conclusions:
- Subcutaneous enoxaparin is a viable alternative to intravenous UFH for acute treatment of unstable coronary artery disease.
- The findings support the use of enoxaparin in a broad spectrum of NSTEMI patients.
- Subgroup analysis highlights specific patient characteristics that may benefit more from enoxaparin therapy.
Background:
Two large-scale phase III clinical trials, the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events (ESSENCE) trial and the Thrombolysis in Myocardial Infarction (TIMI) 11B study, have shown the low-molecular-weight heparin, enoxaparin, to be more effective than unfractionated heparin (UFH) in reducing the risk of death and severe cardiac events in patients with rest unstable angina and/or non-ST-segment elevation myocardial infarction (NSTEMI). However, patients with NSTEMI acute coronary syndromes are a heterogeneous group.
Methods:
A meta-analysis using pooled data from ESSENCE and TIMI 11B was performed to examine the efficacy of enoxaparin in different patient subgroups. In addition, a statistical model was developed to test which factors best predicted an enhanced treatment effect.
Results:
Enoxaparin was more effective than intravenous dose-adjusted UFH in reducing the incidence of the composite endpoint (including death, myocardial infarction or recurrent angina prompting urgent revascularization) in the majority of subgroups at 43 days after randomization. Univariate analyses revealed that there was a greater benefit with enoxaparin in patients with ST-segment deviation or elevated cardiac enzyme markers on admission, women, nonsmokers and patients with characteristics indicative of higher cardiac risk, including prior percutaneous coronary interventions, being at least 65 years old, prior angina and prior aspirin use. Multivariate statistical modelling of treatment effect revealed that ST-segment depression and electrocardiographic changes were the best predictors of an enhanced treatment effect.
Conclusions:
These data reinforce previous evidence suggesting that enoxaparin administered subcutaneously twice daily may be considered as an alternative to intravenous UFH in the acute treatment of a broad range of patients with unstable coronary artery disease.
More Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:26Angina IV: Management
01:20Angina V: Nursing Management
01:29Venous Thrombosis III: Interprofessional Care